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high-risk (stage IIB/C, III) and metastatic (stage IV) melanoma.
METHODS: Data were acquired from Convergence CT, a
company that links longitudinal electronic medical records and
claims data from large physician practices, clinics, ambulatory
centers, and hospitals in the US. Subjects with 1 diagnosis of
malignant melanoma (ICD-9 172.xx, 173.xx, V10.82) from July
1, 2003 November 30, 2006 and pathology-conﬁrmed disease
stage of IIB/C, III, or IV were selected. Additional stage IV
patients were identiﬁed based on evidence of a subsequent ICD-9
code (197.xx, 198.xx) for secondary metastases. Post-diagnosis
prevalence of the key treatments was analyzed descriptively.
Logistic regression was used to assess predictors of therapeutic
choice. RESULTS: A total of 268 subjects were identiﬁed. Stage
distribution was: IIB/C (18%); III (21%); IV (61%). 58% were
65 years of age and 62% were male. Surgery was the predomi-
nant treatment in stage IIB/C and III (received by >80% of
subjects), but was seen in only 38% of stage IV patients. Across
all stages, radiation, chemotherapy, and immunotherapy were
less common (23%, 27%, and 10%, respectively). Being elderly
[odds ratio = 2.19; 95% CI = (1.10–4.35)] and having stage IV
disease [7.31 (2.38–22.39)] was associated with a signiﬁcantly
increased likelihood of receiving no active treatment. Older age
(65+), higher co-comorbidity burden, and having stage IV disease
were associated with a decreased probability of surgery [0.55
(0.30–0.99), 0.92 (0.86–0.99), 0.08 (0.03–0.22), respectively].
Receiving radiation was reduced by older age, but increased by
having stage IV disease [2.38 (0.91–6.22)]. Signiﬁcant predictors
of chemotherapy were stage IV disease [2.65 (1.01–6.93)] and
higher co-morbidity burden [1.08 (1.01–1.17)]. Finally,
increasing age substantially reduced the likelihood of receiving
immunotherapy [0.24 (0.10–0.60)]. CONCLUSION: Factors
inﬂuencing practice patterns and treatment choice in a popula-
tion with high risk or metastatic melanoma. Across therapeutic
choices, age and disease stage were the signiﬁcant predictors.
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OBJECTIVE: Using 12 years of administrative data, we assessed
the trends in the use of breast conserving surgery (BCS) before
and after the release of clinical guidelines on BCS in Japan
(published in 1999 and updated in 2005.) METHODS: We used
a database from the Quality Improvement/Indicator Project that
involved 40 teaching hospitals in Japan. Data on all discharged
cases were collected from these hospitals from 1995. We then
selected female operable breast cancer patients who were
admitted to ﬁve of these hospitals from January 1996 through
September 2007 (n = 1971). A multiple regression analysis was
performed to examine whether the proportion of the use of BCS
after publication of guidelines was higher than that before pub-
lication, after adjusted for the effects of patient’s age, comorbid-
ity status (Charlson Comorbidity Index), hospital, and time
period of admission. The Hosmer-Lemeshow test was conducted
to assess the goodness-of-ﬁt of the model. RESULTS: The pro-
portion of BCS use increased from 16.1% in 1996 to 62.2% in
2007. Multiple logistic regression analysis revealed that patients
who were <50 years old (P < 0.001) and had no comorbidity
(P < 0.001) were signiﬁcantly more likely to receive BCS. The
proportion of BCS use has been substantially higher since 2001,
two years after the BCS guidelines were published in Japan.
Signiﬁcant practice variations of BCS use were also conﬁrmed
among hospitals. CONCLUSION: This study conﬁrmed the lag
time between guideline publication and change in practice of BCS
use. We further need to examine the potential barriers to guide-
line adoption related to physicians’ knowledge and attitudes as
well as external barriers including patient-, guideline-, and
environment-related factors, to explain the reasons of change in
the use of BCS over ten years.
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OBJECTIVE: To document real-world treatment patterns in
elderly patients with high-risk (stage IIB/C, IIIA/B, IIIC) or meta-
static (stage IV) melanoma. METHODS: Data was taken from
the Surveillance, Epidemiology, and End Results (SEER)-
Medicare linked database combining clinical information on
incident cancer cases in the US between 1991 and 2002 with
longitudinal (1991–2005) Medicare claims. Subjects 65 years
with 1 stage IIB or higher melanoma diagnosis and 6 months
of subsequent beneﬁts coverage were selected. We documented
utilization patterns of four major therapies (surgery, radiation,
chemotherapy, immunotherapy) following the diagnosis.
RESULTS: A total of 6470 subjects met all criteria. Stage distri-
bution was: IIB/C (38%); IIIA/B (46%); IIIC (1%); IV (15%).
Median follow-up was 56, 39, 16, and 6 months, respectively.
Surgery (primarily tumor excision) was the predominant 1st line
treatment, received by >85% of subjects with stage IIB/C, IIIA/B,
or IIIC melanoma and 60% of stage IV cases, but was a rare 2nd
line approach. Radiation was 1st line treatment in only 2%, 5%,
and 13% of stage IIB/C, IIIA/B, and IIIC cases, respectively,
but was more common as a 2nd line approach in these subjects
(15%, 24%, and 41%, respectively). Radiation was equally
prevalent (~30% of cases) as 1st or 2nd line treatment in stage IV.
Chemotherapy was uncommon as 1st line treatment (<4% of all
cases), but prevalent as 2nd line therapy (by respective stage,
14%, 20%, 41%, and 22% of cases). Immunotherapy was rare,
except as 2nd line treatment in stage IIIC (26% of cases). CON-
CLUSION: Beyond surgery as a 1st line approach, relatively few
patients received other types of treatment as either 1st or 2nd line
therapy. These ﬁndings demonstrate an unmet need in high risk
and metastatic melanoma. Additional analyses of administrative
data characterizing real-world treatment patterns in melanoma
are needed to help inform the direction of future clinical trials.
GASTROINTESTINAL DISORDERS—
Clinical Outcomes Studies
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OBJECTIVE: Numerous randomized controlled trials (RCTs)
have evaluated efﬁcacy of proton-pump inhibitors (PPIs) in con-
trolling nighttime symptoms of gastroesophageal reﬂux disease
(GERD). Quantitative synthesis of the effect of PPIs on nighttime
symptoms is lacking, thus the validity of performing a meta-
analysis was assessed. METHODS: MEDLINE and EMBASE
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databases from 1990–June 2007 were systematically searched for
RCTs evaluating the efﬁcacy of PPIs on nighttime symptoms in
adults with GERD. Methodological and clinical homogeneity
across studies was explored. Methodological diversity or differ-
ences in study quality evaluated by Jadad score (ranging from
1 = low to 5 = high) and clinical diversity in nighttime criteria
used for patient enrollment, nighttime outcomes measured, and
the nighttime deﬁnition used were explored. RESULTS: Thirty-
two RCTs compared the efﬁcacy of PPI with placebo only (n = 7),
H2-receptor antagonist only (n = 12), another PPI only (n = 11)
or both placebo and H2-receptor antagonist (n = 2) in control-
ling nighttime GERD. The majority of studies (n = 28) were of
high methodological quality (Jadad score of at least 3 points).
Source of data collection was patient daily diaries across all
studies. Criteria for enrolling nighttime GERD patients (fre-
quency and/or severity of nighttime symptoms) lacked consis-
tency. Nighttime heartburn measures varied from percentage of
patients without heartburn (n = 18), percentage of heartburn-
free nights (n = 15), heartburn severity score (n = 11) or time to
heartburn relief (n = 6). Most studies assessed efﬁcacy at eight
weeks or less; only three studies measured the long-term efﬁcacy
of PPI. However, very few nighttime heartburn measures assessed
the same timeframe. The time window for the nighttime
symptom assessment was reported in only three studies and was
not based on speciﬁc hours but on sleep/posture (retiring/lying
down to sleep). CONCLUSION: RCTs of PPI therapy in night-
time GERD are of high methodological quality. However,
presence of clinical heterogeneity across trials in enrollment cri-
teria, outcomes, and timeframes minimizes the possibility of
performing meta-analysis.
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OBJECTIVE: To compare the rate of hospitalizations for serious
upper and lower GI events in patients with increased GI risk
taking a Traditional NSAID (tNSAID)+Proton Pump Inhibitor
(PPI) or a COX-2 selective inhibitor (Coxib), chronic and acute.
METHODS: From the PHARMO Record Linkage System,
including among others linked drug-dispensing and hospital
records of approximately three million individuals in The Neth-
erlands, we selected new users of Coxibs or tNSAIDs between
January 1, 2000 and December 31, 2004. Eligible patients had
1 year history before the 1st NSAID dispensing and 1 year
follow-up which ended at ﬁrst hospitalization for serious GI
event (the outcome), the last dispensing, or the end of the study
period. Chronic users were deﬁned as patients who used any
NSAIDs for 60 days during the ﬁrst year of follow-up
(n = 58770); other NSAID users were acute users (n = 538.420).
Multivariate analysis by Poisson regression adjusted for sex, age,
duration of follow-up, tNSAID and coxib dose, adherence to
NSAIDs or PPIs, gastroprotection, anticoagulants, acetami-
nophen, corticosteroids, and cardiovascular disease. RESULTS:
The cohort included 52,953 new tNSAIDs+PPI users and 80,756
new Coxib users, with main characteristics: mean (SD) age
58.1  15.5 vs. 56.7  17.5; female 55.3% vs. 62.2%; mean
duration of treatment (days): 137  217 vs. 138  179, respec-
tively. Among acute users, adjusted hazard ratios (95% Conﬁ-
dence Interval) of hospitalizations were 0.21 (0.14–0.32) for
upper and 0.26 (0.16–0.42) for lower GI events, for Coxib versus
tNSAIDs+PPI users. Among chronic users, adjusted hazard ratios
were 0.35 (0.22–0.55) for upper GI and 0.43 (0.25–0.75) for
lower GI events, for Coxib versus tNSAIDs+PPI users. CON-
CLUSION: Acute and chronic Coxib users had a statistically
signiﬁcantly lower rate of hospitalizations for upper and lower
GI events compared to tNSAIDS+PPI users. Future research is
needed to explain these ﬁndings, possibly due to prescribing for
non-preventive reasons.
GASTROINTESTINAL DISORDERS—Cost Studies
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OBJECTIVE: Ulcerative colitis (UC) is a chronic condition that
afﬂicts young adults in their economically productive years.
Because of its long duration, UC causes high use of health ser-
vices and high lifetime costs for medical care. The aim of this
study was to measure the annual costs of patients with UC from
the Brazilian public heath perspective and to identify potentially
relevant determinants of costs. METHODS: Thirty-one gastro-
enterologists from southeast Brazil prospectively evaluated all
their UC patients during two months. They used a structured
questionnaire speciﬁcally developed to evaluate resource use by
patients with ulcerative colitis. Costs of medical services (diag-
nostics and treatment) were considered as well as costs of
medication. Resource use was valued using government reim-
bursement for hospital services and government tender prices
drugs. RESULTS: A total of 175 patients were evaluated. The
mean annual cost of one CD patient was R$1945.06, including
medication, physician, laboratory, diagnostic, hospitalization
and surgery costs. Medication, hospitalization, surgery and diag-
nostic procedures accounted respectively for 95%, 3%, 1%, and
1% of the total annual costs. Mesalazine was the most used drug
to initiate UC′s treatment (58%). There was no statistical differ-
ence between the costs of the patients treated with mesalazine
and sulfasalazine. Due to differences in the mean dosage of theses
drugs, mesalazine daily cost is lower than sulfasalazine. CON-
CLUSION: This is the ﬁrst time that UC treatment costs have
been demonstrated from the Brazilian public health perspective.
Although mesalazine is deemed to be more expensive than sul-
fasalazine and considering that there was no statistical difference
in total costs among patients taking mesalazine and sulfasalazine,
and that medications represent more than 90% of total UC
treatment annual costs in the public Brazilian health care system,
the use of mesalazine may represent a reduction factor in the
ﬁnancial resource expenditure for the treatment of UC.
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OBJECTIVE: Inﬂiximab improves patient quality of life and is
effective to control Crohn’s disease refractory to the standard
treatment. It lacks real world Brazilian data demonstrating that
this improvement in quality of life and disease control is related
to decrease of resource use mainly due to hospitalization reduc-
tion in moderate and severe Crohn disease patients receiving
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